No Data
No Data
IceCure Medical Announces Interim Results From ICESECRET Study
Express News | Icecure's Icesecret Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
Earnings Preview: ICCM to Report Financial Results Pre-market on March 27
Express News | Icecure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
IceCure Medical Shares Are Trading Lower. The Company Announced It Is in Continued Discussions With the U.S. FDA Regarding Its De Novo Marketing Authorization Request for ProSense in Early-stage Low Risk Breast Cancer With Endocrine Therapy.
Yubraj : @Jaguar8 brother how about TNON
Yubraj Yubraj : is it in your radar or not?
Jaguar8 OP Yubraj : Yes it is but it will be on stocks with news which i will post later. Still reviewing others stocks with news. It will be included for sure
Yubraj Jaguar8 OP : thank you
72149607 : what u think about VVPR jag bro pre market today?
View more comments...